Grand Mal Seizure Treatment Market is Forecasted to Reach a Value of US $2.58 Billion by 2029
The Business Research Company
The Business Research Company's Grand Mal Seizure Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, November 24, 2025 /EINPresswire.com/ -- What Is The Expected Cagr For The Grand Mal Seizure Treatment Market Through 2025?
The treating grand mal seizures market size has seen persistent growth over the past few years. It is expected to increase from $2 billion in 2024 to $2.08 billion in 2025, with a compound annual growth rate (CAGR) of 4.3%. Factors contributing to this upward trend from the historical period include improvements in neurology, advances in medical technology, the introduction of new medications, advancements in the classification of seizures, as well as legal and social advocacy.
The market for grand mal seizure treatment is predicted to experience robust growth over the next few years, with its value estimated to reach $2.58 billion in 2029, reflecting a compound annual growth rate (CAGR) of 5.5%. This escalation during the projected period can be associated with genetic studies and precision medical practices, telemedicine for distant patient care, regulatory adaptations in accessibility, sophisticated brain imaging methods, and an all-encompassing approach to treatment. Additionally, the key trends to be seen during the forecast period will include worldwide championing for epilepsy awareness, patient-centric care methodologies, broadened research in seizure genetics, community back-up systems, and non-drug treatment strategies.
Download a free sample of the grand mal seizure treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12349&type=smp
What Are The Driving Factors Impacting The Grand Mal Seizure Treatment Market?
The significant rise in epilepsy cases is anticipated to spur the development of the grand mal seizure treatment market. Epilepsy, a neurological disorder characterized by recurrent seizures, is often the cause of grand mal seizures which are severe and violent. The rising incidences call for improved treatments, achievable through grand mal seizure treatment solutions. For instance, the World Health Organization, a United Nations public health entity based in Switzerland, reported in February 2023 that around 50 million people globally were living with epilepsy, marking it as one of the most common neurological conditions. About 5 million people are newly diagnosed with epilepsy each year. Thus, the surge in epilepsy cases stimulates the expansion of the grand mal seizure treatment market.
Which Players Dominate The Grand Mal Seizure Treatment Industry Landscape?
Major players in the Grand Mal Seizure Treatment include:
• Novartis AG
• Sanofi S.A.
• GlaxoSmithKline PLC
• Takeda Pharmaceuticals Inc.
• Mylan N.V.
• UCB Celltech Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited
• Lupin Pharmaceuticals Inc.
What Are The Future Trends Of The Grand Mal Seizure Treatment Market?
Significant players in the grand mal seizure treatment market like Zydus Lifesciences Limited are driving innovation by developing new offerings like anti-epilepsy medications, to stay ahead in the competitive landscape. These are a type of antiepileptic drugs (AEDs) or anticonvulsants, specifically created to manage and mitigate epileptic seizures and parallel diseases. This Indian pharmaceutical firm made a notable stride in January 2023, by launching the Topiramate extended-release capsules in the U.S market, in varying strengths of USP 25 mg, 50 mg, and 100 mg. With this, Zydus became the pioneers to receive the final clearance and launch this generic anti-epilepsy medication in the mentioned strengths. These capsules are intended for epilepsy therapy, especially as initial monotherapy for patients over six years old with partial-onset or primary generalized tonic-clonic seizures, and also for averting migraine in patients over 12 years old.
Global Grand Mal Seizure Treatment Market Segmentation By Type, Application, And Region
The grand mal seizure treatment market covered in this report is segmented –
1) By Type: Barbiturates, Hydantoin, Phenyltriazine, Iminostilbenes, Benzodiazepines, Aliphatic Carboxylic Acids, Other Types
2) By Diagnosis: Magnetic Resonance Imaging (MRI), Electroencephalogram (EEG), Blood Tests, Computed Tomography (CT), Other Diagnosis
3) By Treatment: Antiepileptic Drugs, Surgery, Vagus Nerve Stimulation, Ketogenic Diet, Other Treatments
4) By End Users: Academic And Research Centers, Neurological Centers, Hospitals, Other End Users
Subsegments:
1) By Barbiturates: Phenobarbital, Primidone
2) By Hydantoins: Phenytoin
3) By Phenyltriazines: Lamotrigine
4) By Iminostilbenes: Carbamazepine, Oxcabazepine
5) By Benzodiazepines: Clonazepam, Diazepam, Lorazepam
6) By Aliphatic Carboxylic Acids: Valproic Acid, Divalproex Sodium
7) By Other Types: Levetiracetam, Topiramate, Zonisamide
View the full grand mal seizure treatment market report:
https://www.thebusinessresearchcompany.com/report/grand-mal-seizure-treatment-global-market-report
Which Region Holds The Largest Market Share In The Grand Mal Seizure Treatment Market?
In 2024, North America led the market for grand mal seizure treatment. The report includes regions such as Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa in its grand mal seizure treatment market study.
Browse Through More Reports Similar to the Global Grand Mal Seizure Treatment Market 2025, By The Business Research Company
Generic Central Nervous System Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report
Computed Tomography Ct Scanners Devices And Equipment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/computed-tomography-ct-scanners-devices-and-equipment-global-market-report
Single Photon Emission Computed Tomography Spect Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/single-photon-emission-computed-tomography-spect-global-market-report
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
